Sökning: "hK2"
Visar resultat 1 - 5 av 8 avhandlingar innehållade ordet hK2.
1. Human glandular kallikrein 2 (hK2) in prostate cancer: Clinical and Methodological studies
Sammanfattning : Human glandular kallikrein 2 (hK2) is a predominantly prostate produced protein with many similarities to prostate-specific antigen (PSA). Just like for PSA elevated levels of hK2 can be found in men with protate cancer. We created an assay where hK2 in serum could reliably and with negligible cross-reactivity with PSA, be measured down to 0. LÄS MER
2. Assessments of PSA Forms and hK2 as Very Early Predictors of Prostate Cancer
Sammanfattning : Concentrations of prostate-specific antigen (PSA) and human kallikrein 2 (hK2) were investigated in blood samples that had been obtained from men who were diagnosed with prostate cancer (PCa) decades later. The studies were based on a cohort comprising 22,444 men who, in 1974?1986, were early middle aged and represented a non-PCa-screened population. LÄS MER
3. The Kallikrein-Related Peptidases hK2 and PSA with Emphasis on Genetic Variation, Secretion, and Sperm Motility
Sammanfattning : Prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) are secreted by the prostate into seminal plasma and through leakage into blood. This leakage increases rapidly in prostate disease, and PSA is used worldwide as a marker of prostate cancer. LÄS MER
4. Human Glandular Kallikrein 2
Sammanfattning : Human glandular kallikrein 2 (hK2) is a serine protease, which is predominantly expressed by the prostate gland and found in seminal plasma at mean levels of 6 mg/ml. It has 79% amino acid sequence identity with prostate-specific antigen (PSA or hK3). LÄS MER
5. Radioimmunoimaging and Radioimmunotherapy of Prostate Cancer Preclinical evaluation of kallikrein related peptidase 2 targeting
Sammanfattning : Prostate cancer is one of the major causes of cancer related deaths in men in Europe and the United States. In this doctoral thesis, radioimmunoimaging and -therapy of prostate cancer was investigated pre-clinically by targeting the human kallikrein-related peptidase 2 (hK2) with radiolabelled monoclonal antibodies. LÄS MER